ASCO GU 2024

Combination vs. monotherapy - a great new option for…

Is "more" always better?

BRCAAway - practice changing or hypothesis generating…

What about the clinical benefit?

Localized PCa - news for radiotherapy and biochemical…

Olaparib + Arbiraterone better compared to either alone

Cognitive function in ART treatment

Gleason 3+3 - cancer or not?

Long-term dose escalation - Therapy in high-risk…

First positive study of IO therapy in mCRPC

Stockholm3 validated in multiethnic cohort

Combination NHT + PARP makes sense

Relugolix combined with androgen signaling in real word…

Salvage radiation with anti-androgen superior to…

Higher radiation is effective in high-risk PCA

Evaluating the recombination-repair mutations in…

Further testing before olaparib combination

Insights and news for mCRPC

Quality of life under intensive therapy

Combination of cabozantinib & checkpoint inhibitor

Dose de-escalation in different ways

BRCAaway - PARP combination study

Still a difficult time for androgenic inhibitors in…

Enzalutamide therapy as option for biochemical…

mCRPC de Olaparib+Abi , tek tek herbirinden ustun

Kombination av cabozantinib och immunterapi

Gleason 3+3 ska vi kalla de cancer eller inte?

Une période encore difficile pour les inhibiteurs…

PCa Tedavisinde Deeskalasyon (Tedavi Azaltimi) Orta…

SEPTA calismasi: Stockholm3 un multietnik hasta…

Κορυφαίες Στιγμές για τον Καρκίνο του Προστάτη στο ASCO…

Post-RP salvage radyoterapi hormonoterapi ile konbine…

BRCAAway - PARP hämmare, abiraterone eller i…

Advances in (neo)-adjuvant treatment in urothelial…

The emerging field of biomarkers in bladder cancer

ADC + ICI: new data for platinum-refractory bladder…

Adjuvant Nivolumab Shows Promise in Boosting Long-Term…

Adjuvant therapy in urothelial carcinoma : is the…

Highlights in bladder cancer at ASCO GU24

HER2 and bladder cancer

Perioperative adjuvant therapy in urothelial cancer

ASCO GU24 - Highlights in Bladder cancer

MIBC: adjuvant PD1 - all set?!

Update M1 urothelial cancer

Another success for an ICI?

Update on EV-302

EV as standard in 3rd line mUC

Biomarker update

Should we start forgetting the Galsky Criteria in…

EV + Pembro new first-line standard in localized…

Terapia adyuvante perioperatoria en el cáncer de vejiga

Encore un succès pour une ICI ?

¿Deberíamos empezar a olvidarnos de los Criterios de…

Novedades sobre EV-302

νέα δεδομένα για το ουροθηλιακο καρκίνωμα από ASCO GU24

Adjuvant therapy in kidney cancer: Is immunotherapy the…

Subcutaneous vs. intravenous application: ready for…

No surprise with the QoL data

Tumorburden and outcome

Practice changing adjuvant therapy?!

ASCO GU24 - Highlights in renal cell carcinoma

Highlights in kidney cancer at ASCO GU24

Perioperative treatment in renal cell carcinoma - did…

Long-term follow-up of first-line trials

Subcutaneous Nivolumab Matches IV Formulation in Clear…

Durable effects of Ipi-Nivo

Better QoL with Belzutifan

Cabozantinib Plus Atezolizumab in Adrenocortical…

Long-Term Data on NIVO+IPI in aRCC

Nivolumab/Cabozantinib Outshines Sunitinib in Landmark…

Belzutifan: Updates on QoL

Long-term outcome

νέα δεδομένα για το ουροθηλιακο καρκίνωμα από ASCO GU24